Publication details
Lucentis v léčbě vlhké formy VPMD
| Title in English | Lucentis in treatment of wet form of AMD |
|---|---|
| Authors | |
| Year of publication | 2009 |
| Type | Article in Proceedings |
| Conference | Sborník abstrakt XVII. výročního sjezdu České oftalmologické společnosti |
| MU Faculty or unit | |
| Citation | |
| Field | ORL, ophthalmology, stomatology |
| Keywords | age related macular degeneration; choroidal neovascular membrane; vascular endothelial growth factor; ranibizumab |
| Description | The authors evaluated results achieved with the use of ranibizumab (Lucentis) for wet age-related macular degeneration (AMD). Ranibizumab (Lucentis, Novartis) is an antagonist of vascular growth factor (VEGF), approved for intraocular injection in wet form of age-related macular degeneration (AMD). Ranibizumab in our department used to treat patients with occult, minimally classic or predominantly classic subretinal neovascular membrane (CNV) in the subfoveal location. At the beginning of treatment and before any application is examined best-corrected visual acuity on ETDRS optotypes (number of characters is determined that the patient could see the optotypes). To assess the effectiveness of treatment at baseline and before each application, OCT examination was performed (Stratus OCT). Treatment of patients at the time of writing the abstract is still ongoing. Results will be presented to Congress on the ground to achieve the longest follow-up period for all subjects included in the file. |